ACCELERON PHARMA INC. (NASDAQ:XLRN) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
previously announced Annual Meeting of Stockholders (the Annual
Meeting), at which a quorum was present.
the following three proposals: (i) to elect Jean M. George,
George Golumbeski, Ph.D., Thomas A. McCourt and Francois Nader,
M.D. as Class I members of the Company’s board of directors,
each for a three year term (“Proposal 1”); (ii) to approve, on
an advisory basis, the compensation paid to the Company’s named
executive officers as described in the proxy statement
(“Proposal 2”); and (iii) to ratify the selection of Ernst
Young LLP as the Companys independent registered public
accounting firm for the fiscal year ending December 31, 2017
(“Proposal 3”).
listed below to the Companys board of directors. The votes cast
at the Annual Meeting for Proposal 1 were as follows:
|
Nominees
|
|
|
For
|
|
Withheld
|
|
Broker Non-Votes
|
|||
|
Jean M. George
|
|
30,102,012
|
|
|
2,459,855
|
|
|
2,960,483
|
|
|
|
George Golumbeski, Ph.D.
|
|
32,472,104
|
|
89,763
|
|
2,960,483
|
||||
|
Thomas A. McCourt
|
|
32,309,137
|
|
|
252,730
|
|
|
2,960,483
|
|
|
|
Francois Nader, M.D.
|
|
32,495,822
|
|
66,045
|
|
2,960,483
|
advisory basis, the compensation paid to the Company’s named
executive officers as described in the proxy statement. The votes
cast at the Annual Meeting for Proposal 2 were as follows:
|
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
||||
|
27,619,691
|
|
|
4,927,521
|
|
|
14,655
|
|
|
2,960,483
|
|
Young LLP as the Companys independent registered public
accounting firm for the fiscal year ending December 31, 2017. The
votes cast at the Annual Meeting for Proposal 3 were as follows:
|
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
||||
|
35,491,602
|
|
|
30,001
|
|
|
|
|
|
issued a joint press release titled “Celgene and Acceleron
Complete Target Enrollment in the MEDALIST and BELIEVE Phase 3
Studies of Luspatercept in Myelodysplastic Syndromes and
Beta-Thalassemia.”
Current Report on Form 8-K and is incorporated herein by
reference.
|
Exhibit Number
|
Description of Exhibit
|
|
|
99.1
|
Press release of Celgene Corporation and Acceleron
Pharma Inc. dated June 1, 2017 |
About ACCELERON PHARMA INC. (NASDAQ:XLRN)
Acceleron Pharma Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutic candidates that are based on mechanisms, which the human body uses to regulate the growth and repair of its cells and tissues. Its therapeutic candidates are used to treat serious and rare diseases. The Company’s pipeline includes Luspatercept, Sotatercept, Dalantercept, ACE-083, ACE-2494, ACE-1332, ACE-3891, ACE-2798, ACE-2536 and ACE-2395. Luspatercept promotes red blood cell production. It is developing Sotatercept for the treatment of chronic kidney disease. Dalantercept treats cancers by inhibiting blood vessel formation by inhibiting signaling through the activin receptor-like kinase (ALK) 1 receptor. ACE-083 is for the treatment of focal muscle disorders. ACE-2494 is designed to treat systemic muscle disorders. ACE-3891, ACE-1332, ACE-2798, ACE-2536 and ACE-2395 are in preclinical stage of development.
